---
title: "Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials | LLY Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286163902.md"
description: "Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials | LLY Stock News"
datetime: "2026-05-12T14:05:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286163902.md)
  - [en](https://longbridge.com/en/news/286163902.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286163902.md)
---

# Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials | LLY Stock News

Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials | LLY Stock News

### Related Stocks

- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)

## Related News & Research

- [Eli Lilly (LLY) Is Up 6.0% After Obesity Drug Data And $4.5B Manufacturing Push - Has The Bull Case Changed?](https://longbridge.com/en/news/286629257.md)
- [Eli Lilly Says Newly Approved Foundayo, Lower-Dose Zepbound Help Sustain Weight Loss](https://longbridge.com/en/news/286288742.md)
- [Eli Lilly (LLY) Is the Face of the Obesity Boom. Has the Market Already Priced It In?](https://longbridge.com/en/news/286727957.md)
- [<![CDATA[Pharmaceutical Executive Daily: Rigel Pharmaceuticals Enters an Exclusive Global Licensing Agreement with Arvinas and Pfizer for Veppanu]]>](https://longbridge.com/en/news/286303707.md)
- [Patients don't regain much weight switching from injections to Lilly's weight-loss pill, study finds](https://longbridge.com/en/news/286163551.md)